CXBS (Corix Bioscience) Current Deferred Revenue: $0.00 Mil (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Corix Bioscience Current Deferred Revenue?

Corix Bioscience CXBS -99.00% Current Deferred Revenue is $0.00 Mil as of Sep. 2017.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Corix Bioscience's current deferred revenue for the quarter that ended in Sep. 2017 was $0.00 Mil.

Corix Bioscience Current Deferred Revenue Related Terms

Corix Bioscience Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Corix Bioscience's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience Current Deferred Revenue Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.01

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.00 0.00 0.00
What does a Current Deferred Revenue of $0.00 Mil mean?
Corix Bioscience (CXBS) has a Current Deferred Revenue of $0.00 Mil as of Sep. 2017. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Corix Bioscience and its competitors.
Is Corix Bioscience's Current Deferred Revenue too high?
Corix Bioscience's current Current Deferred Revenue is $0.00 Mil.
How does Corix Bioscience's Current Deferred Revenue compare to BKIT and YBAO?
Corix Bioscience's Current Deferred Revenue of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Corix Bioscience and its competitors. Corix Bioscience's current Current Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current Current Deferred Revenue of $0.00 Mil. The current Current Deferred Revenue is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current Current Deferred Revenue is $0.00 Mil as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corix Bioscience Business Description

Address 18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.